Sulthiame is in development for the treatment of self-limiting epilepsy with centrotemporal spikes in children. A self-limiting epilepsy with centrotemporal spikes is defined as an age-dependent epilepsy, with a typical onset at 5–8 years that usually subsides by the teenage years. The main symptom of the condition is seizures lasting between 1 – 3 mins. It is a hereditary health condition. Generally, epilepsy cannot be controlled by current antiseizure medications in at least 30% of patients so new treatments are needed.
